Biopharming Regulations | GenomeWeb

Using genetic engineering in plants to create biopharmed drugs holds all sorts of promise for treating diseases, as the recent case of a drug which appears to have cured two Ebola patients has shown, but regulators may be holding this field back, argues Henry Miller in a Wall Street Journal op-ed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.